Hikma and Emergent BioSolutions Join Forces
Hikma Pharmaceuticals PLC has announced a significant exclusive commercial partnership with Emergent BioSolutions, focusing on the sale of KLOXXADO® (naloxone HCl) nasal spray 8 mg in North America. This collaboration aims to enhance the distribution of KLOXXADO®, ensuring it reaches those who need it most. KLOXXADO® has gained recognition since its approval by the FDA, aimed specifically at providing emergency treatment for known or suspected opioid overdoses.
KLOXXADO®: A Vital Medical Solution
KLOXXADO® plays a crucial role in addressing the opioid crisis by quickly reversing the effects of an overdose. Opioid overdoses can lead to severe respiratory depression, making timely intervention critical. The partnership will leverage Emergent's marketing expertise to improve access to KLOXXADO® across various settings, including hospitals and community organizations.
Key Features of the Partnership
Under the terms of their six-year agreement, Emergent will take over the sales and marketing of KLOXXADO® in the U.S. and Canada, expanding its naloxone product lineup. Hikma will continue its production efforts at its facility in Columbus, Ohio, ensuring that the product remains readily available. This collaboration is a crucial step towards making naloxone more accessible to those at risk of opioid overdose.
The Importance of Naloxone
Naloxone hydrochloride is an essential medication that can reverse the life-threatening effects of opioid overdose. It is designed to restore normal breathing in individuals who have overdosed on opioids, responding quickly even in emergencies. Every moment counts during an overdose, and having naloxone on hand can save lives.
Expert Insights from Hikma's Leadership
Hafrun Fridriksdottir, President of Hikma's Generics division, expressed enthusiasm about this strategic partnership, stating, "We are thrilled to be partnering with Emergent, who have deep experience in getting lifesaving naloxone nasal spray into the hands of those who can use it to help save lives." This partnership combines Hikma's manufacturing capabilities with Emergent's established commercial expertise, creating a synergy that is aimed at broadening access to this critical drug.
About Hikma Pharmaceuticals
Hikma Pharmaceuticals PLC is a global leader in pharmaceuticals, dedicated to enhancing health outcomes worldwide. For over 45 years, the company has focused on creating high-quality medications that are accessible to those in need. Headquartered in the UK, Hikma operates in multiple regions, including North America and Europe, leveraging its advanced technology to develop innovative solutions that address health challenges.
Contact Information
For any inquiries regarding this partnership or more information about Hikma, interested parties can reach out to their investor relations team through the provided channels. The company is committed to transparency and support for its investors and stakeholders.
Frequently Asked Questions
1. What is KLOXXADO® used for?
KLOXXADO® is a nasal spray used for the emergency treatment of known or suspected opioid overdoses, quickly reversing the effects of opioids and restoring normal breathing.
2. How does the partnership benefit patients?
This partnership ensures that KLOXXADO® is more widely available, thereby helping to save lives during opioid overdose emergencies by enhancing accessibility across North America.
3. What is the production process for KLOXXADO®?
KLOXXADO® is produced at Hikma's manufacturing facility in Columbus, Ohio, ensuring high-quality and consistent delivery of the product to Emergent for distribution.
4. How can someone obtain KLOXXADO®?
KLOXXADO® will be available through various healthcare providers, pharmacies, and outreach programs focused on combating opioid overdoses, thanks to the enhanced marketing efforts by Emergent.
5. Who benefits from the availability of naloxone?
The availability of naloxone, including KLOXXADO®, benefits anyone at risk of opioid overdose, including patients, family members, caregivers, and the public health community.
